Welcome to our dedicated page for Compass Pathways Plc news (Ticker: CMPS), a resource for investors and traders seeking the latest updates and insights on Compass Pathways Plc stock.
Compass Pathways plc (Nasdaq: CMPS) generates frequent news as it advances COMP360, its investigational synthetic psilocybin treatment, through late-stage clinical development for serious mental health conditions. The company focuses on treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD), and its updates often highlight progress in these programs, regulatory interactions, and collaborations related to potential delivery models.
News items for CMPS commonly cover clinical trial milestones, such as Phase 3 results in TRD and the design and initiation of late-stage trials in PTSD. For example, Compass has reported achievement of the primary endpoint in its COMP005 Phase 3 trial in TRD and the U.S. Food and Drug Administration’s acceptance of an Investigational New Drug application for COMP360 in PTSD, enabling a Phase 2b/3 trial. Publications of clinical data in peer-reviewed journals, including results from a Phase 2 PTSD study, are also featured.
Investors and observers can also expect announcements about strategic collaborations with healthcare organizations and clinic networks. These collaborations, including those with Radial Health, Greenbrook Mental Wellness Centers, Hackensack Meridian Health, Reliant Medical Group, Journey Clinical, Mindful Health Solutions, and HealthPort, are described as helping to inform how investigational COMP360 treatment might be integrated into various care settings if approved.
Additional CMPS news includes financial results, participation in investor and healthcare conferences, and corporate governance developments such as board appointments. Together, these updates provide context on Compass Pathways’ clinical, regulatory, and operational progress as it pursues evidence-based innovation in mental health. Readers interested in CMPS can use this news feed to follow key developments in the company’s COMP360 programs and broader mental health biotechnology strategy.
COMPASS Pathways (Nasdaq: CMPS) has appointed Dr. Wayne J. Riley to its Board of Directors, aiming to enhance its leadership in the mental health sector. Dr. Riley, with over 25 years of experience in healthcare and academia, is currently the President of SUNY Downstate Health Sciences University. His expertise is expected to support COMPASS's innovation in psilocybin therapy for treatment-resistant depression, which has received Breakthrough Therapy designation from the FDA. This appointment comes as COMPASS conducts a phase IIb clinical trial across 22 sites in Europe and North America.
COMPASS Pathways (Nasdaq: CMPS), a mental health care firm, has been granted two new US patents for their synthetic psilocybin formulations aimed at treating major depressive disorder (MDD), including treatment-resistant depression (TRD). Patent No. 10,954,259 was awarded on March 23, 2021, covering crystalline psilocybin and its pharmaceutical formulations. Patent No. 10,947,257 was granted on March 16, 2021, focusing on oral dosage forms of psilocybin. These patents support COMPASS's phase IIb clinical trial for TRD therapy, with anticipated data release in late 2021.
COMPASS Pathways reported progress in its phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, with data expected by the end of 2021. The company launched its first Centre of Excellence at Sheppard Pratt in Baltimore to advance mental health care. Financially, COMPASS faced a net loss of $60.3 million in 2020, an increase from $19.6 million in 2019, driven by rising R&D and administrative expenses. Cash reserves stood at $190.3 million by year-end 2020. A conference call is scheduled for March 9, 2021.
COMPASS Pathways (Nasdaq: CMPS) has announced an expansion of its Discovery Center through collaborations with leading scientists from UC San Diego and Medical College of Wisconsin. The new partners, Adam Halberstadt and John McCorvy, will join Jason Wallach in efforts to develop innovative psychedelic compounds targeting mental health issues. This initiative aims to address unmet medical needs and enhance the existing psilocybin therapy model. COMPASS will hold exclusive rights to the new compounds developed during this collaboration.
COMPASS Pathways (Nasdaq: CMPS) has published a paper in Frontiers in Psychiatry detailing its structured therapist training programme for psilocybin therapy. The program aims to ensure consistent quality in psychological support during COMP360 psilocybin therapy, currently in phase IIb clinical trials for treatment-resistant depression. Developed with leading experts, it includes online learning, in-person training, and ongoing mentorship. This initiative addresses previous inconsistencies in training, enhancing the safety and effectiveness of psilocybin therapy.
Summary not available.
COMPASS Pathways plc (Nasdaq: CMPS) announced participation in two upcoming investor conferences during the week of January 11, 2021. CEO George Goldsmith and President Lars Wilde will engage in a fireside chat available on demand from January 11-14 at the HC Wainwright BioConnect 2021 Conference. Additionally, they will present a business update and conduct a live fireside chat at 12:15 pm ET on January 14 during the Westwicke Healthcare Day at the ICR Conference 2021. Webcasts will be accessible through the COMPASS website's Investors section for 30 days post-event.
COMPASS Pathways (CMPS) successfully completed a $146.6 million IPO on Nasdaq, enhancing their financial position for advancing mental health innovations. They are progressing with their phase IIb clinical trial of COMP360 psilocybin therapy for treatment-resistant depression, expanding to 21 sites across 10 countries. The company strengthened its leadership team with key appointments. As of September 30, 2020, cash and equivalents reached $196.5 million, expected to fund operations into 2023. However, the net loss increased to $16.7 million for Q3 2020, compared to $5.7 million in Q3 2019.
Summary not available.
COMPASS Pathways has successfully closed its initial public offering, selling 8,625,000 American Depositary Shares (ADS) at $17.00 each, totaling gross proceeds of $146.6 million. This includes the full exercise of underwriters' options for an additional 1,125,000 ADS. The ADS began trading on the Nasdaq Global Select Market under the ticker symbol CMPS on September 18, 2020. The offering was managed by Cowen, Evercore ISI, Berenberg, Canaccord Genuity, and H.C. Wainwright & Co.